Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
ClinicalTrials.gov Identifier:
NCT01287039
First received: January 28, 2011
Last updated: May 26, 2016
Last verified: May 2016

January 28, 2011
May 26, 2016
April 2011
December 2013   (final data collection date for primary outcome measure)
  • Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization CAEs were adjudicated by committee to assure consistency.

    Adjusted CAE rate and confidence intervals were based on Negative Binomial regression model adjusted for stratification factors.

    Results are offered as adjusted means.

  • Frequency of Each of the Two Criteria for Clinical Asthma Exacerbations (CAEs) [ Time Frame: Day 1 to Week 52 ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.

    CAEs were adjudicated by committee to assure consistency. Adjusted CAE rate and confidence intervals for the two criteria were based on Negative Binomial regression model adjusted for stratification factors.

    Results are offered as adjusted means.

  • A reduction in the frequency (i.e., number) of clinical asthma exacerbations (CAEs) [ Time Frame: during the full treatment period of 52 weeks ] [ Designated as safety issue: No ]
  • Overall change in forced expiratory volume in 1 second (FEV1) [ Time Frame: From baseline to Week 16, or the onset of first CAE, whichever occurs first ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01287039 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12 and 16 ] [ Designated as safety issue: No ]

    FEV1 is a standard measurement of air movement in the lungs of patients with asthma obtained from pulmonary function tests. It is the volume of air expired in the first second of a forced expiration using a spirometer. Positive change from baseline scores indicate improvement in asthma control.

    The during treatment (Weeks 4, 8, 12 and 16) average FEV1 was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

  • Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) to Week 16 [ Time Frame: Day 1 (baseline, pre-dose), Week 16 ] [ Designated as safety issue: No ]

    The AQLQ is a 32-item instrument administered as a self-assessment (Juniper et al 1992). The questionnaire is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Patients were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (1=severe impairment, 7=no impairment). The overall AQLQ score is the mean of all 32 responses. Five of the activity questions were "patient-specific," which means that each patient identified and scored 5 activities in which the patient was limited by asthma; these 5 activities were identified at the first visit and retained for all subsequent follow-up visits.

    Positive change from baseline scores indicate improvement in quality of life.

  • Change From Baseline in Asthma Control Questionnaire (ACQ) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    The ACQ is a 7-item instrument that measures asthma control (Juniper et al 1999). Six questions are self-assessments; the seventh item, completed by a member of the study staff, is the result of the patient's FEV1 measurement. Each item has 7 possible answers on a scale of 0 to 6, and the total score is the mean of all responses (the total scale is therefore 0-6). A higher score is an indication of poorer asthma control. The during treatment (Weeks 4, 8, 12 and 16) average ACQ was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline scores indicate improvement in asthma control.

  • Kaplan-Meier Estimates for Time to First Clinical Asthma Exacerbation (CAE) [ Time Frame: Day 1 to Day 478 (longest treatment time plus 2 weeks) ] [ Designated as safety issue: No ]

    An exacerbation event was considered a CAE if the patient met either or both of the criteria listed below and this was corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

    • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days; or an increased 2 or more fold for at least 3 or more days for patient's already on corticosteroids.
    • asthma-related emergency treatment, such as an unscheduled visit to the physician's office or emergency room for nebulizer treatment or other urgent treatment to prevent worsening of asthma symptoms, or an asthma-related hospitalization.

    CAEs were adjudicated by committee to assure consistency. The distributions were compared by a log rank test stratified by baseline usage of oral corticosteroid (yes or no) and geographical region (US or other).

  • Change From Baseline in Asthma Symptom Utility Index (ASUI) Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    The ASUI is an 11-item instrument designed to assess the frequency and severity of asthma symptoms and side effects, weighted by patient preferences (Revicki et al 1998). ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms.

    The during treatment (Weeks 4, 8, 12 and 16) average ASUI was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Positive change from baseline values indicate improvement in asthma symptoms. Information was obtained from questionnaire about asthma symptoms.

  • Change From Baseline in Short-Acting Beta-Agonist (SABA) Use Over 16 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16 ] [ Designated as safety issue: No ]

    SABA are used for quick relief of asthma symptoms. To measure SABA use, at each clinical visit patients were asked to recall their usage of SABA therapy within the last 3 days of the scheduled visit. If usage was confirmed, the number of puffs used was recorded. For the purpose of summaries, an average daily usage was evaluated by dividing the total number of puffs recorded over 3 days by 3.

    The during treatment (Weeks 4, 8, 12 and 16) SABA use was estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline scores indicate improvement in asthma control.

  • Change From Baseline in Blood Eosinophil Count Over 16 Weeks and 52 Weeks Using Mixed Model for Repeated Measures [ Time Frame: Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 or early withdrawal ] [ Designated as safety issue: No ]

    Blood eosinophil counts were measured using a standard complete blood count (CBC) with differential blood test at each scheduled visit, and from all patients experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.

    The during treatment average eosinophil counts were estimated using a mixed-effect model for repeated measures (MMRM) with fixed effects (treatment, stratification factors, sex, visit, interaction of treatment and visit), covariates (height, baseline value), and patient as the random effect for the repeated measurements.

    Negative change from baseline values correlate to reduced asthma severity.

  • Participants With Treatment-Emergent Adverse Events [ Time Frame: Day 1 (post-dose) to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]
    An adverse event was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.
  • Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Abnormal Lab Values [ Time Frame: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]

    Data represents participants with potentially clinically significant (PCS) abnormal serum chemistry, hematology, and urinalysis values.

    Significance criteria:

    • Blood urea nitrogen: >=10.71 mmol/L
    • Uric acid: M>=625, F>=506 μmol/L
    • Aspartate aminotransferase: >=3*upper limit of normal (ULN). Normal range is 10-43 U/L
    • Alanine aminotransferase: >=3*ULN. Normal range is 10-40 U/L
    • GGT = gamma-glutamyl transpeptidase: >= 3*ULN. Normal range is 5-49 U/L.
    • Bilirubin: >=34.2 μmol/L
    • White blood cells: <=3.0 or >20 10^9/L
    • Hemoglobin: M<=115, F<=95 g/dL
    • Hematocrit: M<0.37, F<0.32 L/L
    • Neutrophils: <=1.0 10^9/L
    • Eosinophils: >10.0 %
    • Platelets: <75 or >=700 10^9/L
    • Urinalysis: blood, glucose, ketones and total protein: >=2 unit increase from baseline
  • Participants With Treatment-Emergent Potentially Clinically Significant (PCS) Vital Signs Values [ Time Frame: Week 4 to Week 65. The last postbaseline value for approximately 20 patients in each ] [ Designated as safety issue: Yes ]

    Data represents participants with potentially clinically significant (PCS) vital sign values.

    Significance criteria

    • Sitting pulse - high 12-17 yr: >100 and increase of >= 30 beats/minute (bpm)
    • Sitting pulse - low >=18 yr: <50 and decrease of >=30 bpm
    • Sitting pulse - high >=18 yr: >100 and increase of >=30 bpm
    • Sitting systolic blood pressure - low >=18 yr: <90 and decrease of >=30 mmHg
    • Sitting systolic blood pressure - high >=18 yr: >160 and increase of >=30 mmHg
    • Sitting diastolic blood pressure - low 12-17 yr: <55 and decrease of >=12 mmHg
    • Sitting diastolic blood pressure - low >=18 yr: <50 and decrease of >=12 mmHg
    • Sitting diastolic blood pressure - high >=18 yr: >100 and increase of >=12 mmHg
    • Respiratory rate >=18 yr: >24 and increase of >=10 breaths/minute
    • Body temperature - low 12-17 yr: <96.5° Fahrenheit or <35.8° Celsius
    • Body temp - low >=18 yr: <96.5° F or <35.8° C
    • Body temp - high >=18 yr: >100.5° Fahrenheit
  • Participants With a Positive Anti-Reslizumab Antibody Status During Study [ Time Frame: Weeks 16, 32, 48 and 52 ] [ Designated as safety issue: Yes ]
    The immunogenicity of reslizumab was assessed by measuring for the presence of anti-reslizumab antibodies at baseline, weeks 16, 32, 48, and 52 or early withdrawal. Blood samples for anti-reslizumab antibodies assessment were also obtained from all patients (inside or outside of the US) experiencing a serious adverse event, an adverse event leading to withdrawal, or an exacerbation of asthma symptoms.
  • Lung function as measured by Forced Expiratory Volume (FEV1) [ Designated as safety issue: No ]
  • Lung function as measured by percent predicted Forced Expiratory Volume in 1 second (%FEV1) [ Designated as safety issue: No ]
  • Lung function as measured by Forced Vital Capacity (FVC) [ Designated as safety issue: No ]
  • Lung function as measured by Forced Expiratory Flow at 25% to 75% of FVC (FEF25-75%) [ Designated as safety issue: No ]
  • Measurement of time to first clinical asthma exacerbation (CAE) [ Designated as safety issue: No ]
  • Document the courses of oral corticosteroids prescribed for asthma worsening (3 or more days of administration or doubling of current dose) [ Designated as safety issue: No ]
  • Short-acting Beta-agonist usage [ Time Frame: during the entire 52 week treatment period ] [ Designated as safety issue: No ]
  • Blood eosinophil count [ Designated as safety issue: No ]
  • Asthma symptoms as measured by the Asthma Symptom Utility Index (ASUI) [ Designated as safety issue: No ]
  • Asthma control as measured by the Asthma Control Questionnaire (ACQ) [ Designated as safety issue: No ]
  • Quality of life as measured by the Asthma Quality of Life Questionnaire (AQLQ) [ Designated as safety issue: No ]
  • Safety and tolerability of reslizumab treatment in patients with eosinophilic asthma [ Time Frame: during the entire 52 week treatment period ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.

Demonstrate the efficacy of reslizumab, at a dose of 3 mg/kg administered iv every 4 weeks over 12 months, as assessed by the reduction in frequency of clinical asthma exacerbations (CAEs) during 12 months.

An exacerbation event will be considered a CAE if the patient meets either or both of the criteria listed below and this is corroborated with at least 1 other measurement to indicate the worsening of clinical signs and symptoms of asthma:

  • use of systemic, or an increase in the use of inhaled, corticosteroid treatment for 3 or more days
  • asthma-related emergency treatment The above criteria must be corroborated with at least 1 other measurement to indicate worsening in the clinical signs and symptoms of asthma.
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Eosinophilic Asthma
  • Drug: Reslizumab
    Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
    Other Names:
    • Cinquil
    • humanized monoclonal antibody
    • CEP-38072
  • Drug: Placebo
    Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
  • Placebo Comparator: Placebo
    Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
    Intervention: Drug: Placebo
  • Experimental: Reslizumab 3.0 mg/kg
    Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
    Intervention: Drug: Reslizumab
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May;3(5):355-66. doi: 10.1016/S2213-2600(15)00042-9. Epub 2015 Feb 23. Erratum in: Lancet Respir Med. 2015 Apr;3(4):e15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
489
March 2014
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • The patient is male or female, 12 through 75 years of age, with a previous diagnosis of asthma.
  • The patient has had at least 1 asthma exacerbation requiring oral, intramuscular (im), or intravenous (iv) corticosteroid use for at least 3 days over the past 12 months before screening.
  • The patient has a current blood eosinophil level of at least 400/μl.
  • The patient has airway reversibility of at least 12% to beta-agonist administration.
  • The patient has an ACQ score of at least 1.5 at the screening and baseline (before the 1st dose of study drug) visits.
  • The patient is taking inhaled fluticasone at a dosage of at least 440 μg, or equivalent, daily. Chronic oral corticosteroid use (no more than 10 mg/day prednisone or equivalent) is allowed. If a patient is on a stable dose, eg, 2 weeks or more of oral corticosteroid treatment at the time of study enrollment, the patient must remain on this dose throughout the study. The patient's baseline asthma therapy regimen (including but not limited to inhaled corticosteroids, oral corticosteroids up to a maximum of 10 mg of prednisone daily or equivalent, leukotriene antagonists, 5-lipooxygenase inhibitors, or cromolyn) must be stable for 30 days prior to screening and baseline, and must continue without dosage changes throughout study.
  • All female patients must be surgically sterile, 2 years postmenopausal, or must have a negative pregnancy test ß-human chorionic gonadotropin [ß-HCG]) at screening (serum) and baseline (urine).
  • Female patients of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
  • Written informed consent is obtained. Patients 12 through 17 years old must provide assent.
  • The patient is in reasonable health (except for diagnosis of asthma) as judged by the investigator, and as determined by a medical history, medical examination, ECG evaluation (at screening), serum chemistry, hematology, and urinalysis.

    • Other criteria apply; please contact the investigator for more information.

Exclusion Criteria:

  • The patient has a clinically meaningful co-morbidity that would interfere with the study schedule or procedures, or compromise the patient's safety.
  • The patient has known hypereosinophilic syndrome.
  • The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer). Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia (eg, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis) will also be excluded.
  • The patient is a current smoker (ie, has smoked within the last 6 months prior to screening).
  • The patient is using systemic immunosuppressive or immunomodulating or other biologic agents (including, but not limited to, anti-IgE mAb, methotrexate, cyclosporin, interferon-α, or anti-tumor necrosis factor [anti TNF] mAb) within 6 months prior to screening.
  • The patient has previously received an anti-hIL-5 monoclonal antibody (eg, reslizumab, mepolizumab, or benralizumab).
  • The patient has any aggravating medical factors that are inadequately controlled (eg, rhinitis, gastroesophageal reflux disease, and uncontrolled diabetes).
  • The patient has participated in any investigative drug or device study within 30 days prior to screening.
  • The patient has participated in any investigative biologics study within 6 months prior to screening.
  • Female patients who are pregnant, nursing, or, if of childbearing potential, and not using a medically accepted, effective method of birth control (eg, barrier method with spermicide, abstinence, IUD, or steroidal contraceptive [oral, transdermal, implanted, and injected]) are excluded from this study. NOTE: Partner sterility alone is not considered an acceptable form of birth control.

    • Other criteria apply; please contact the investigator for more information.
Both
12 Years to 75 Years   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Belgium,   Chile,   Colombia,   Czech Republic,   Denmark,   Hungary,   Israel,   Malaysia,   New Zealand,   Philippines,   Poland,   Russian Federation,   South Africa,   Sweden,   Thailand
Netherlands
 
NCT01287039
C38072/3082
Not Provided
Not Provided
Not Provided
Teva Branded Pharmaceutical Products, R&D Inc.
Teva Branded Pharmaceutical Products, R&D Inc.
Not Provided
Study Director: Medical Expert, MD TEVA
Teva Pharmaceutical Industries
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP